Radiation-induced apoptosis of peripheral blood lymphocytes is correlated with histological regression of rectal cancer in response to preoperative chemoradiotherapy

Annals of Surgical Oncology

Volumn 19, Issue 4, 2012, Pages 1192-1198

  Ishihara, Soichiro ^a   Iinuma, Hisae ^a   Fukushima, Yoshihisa ^a   Akahane, Takuya ^a   Horiuchi, Atsushi ^a   Shimada, Ryu ^a   Shibuya, Hajime ^a   Hayama, Tamuro ^a   Yamada, Hideki ^a   Nozawa, Keijiro ^a   Matsuda, Keiji ^a   Watanabe, Toshiaki ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; UFT;

AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; MALE; PERIPHERAL LYMPHOCYTE; PREOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE PERIOD; RADIATION INDUCED APOPTOSIS; RADIOSENSITIVITY; RECTUM CANCER; RETROSPECTIVE STUDY;

AGED; APOPTOSIS; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RECTAL NEOPLASMS; REMISSION INDUCTION;

EID: 84862487562     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2057-9     Document Type: Article

References (28)

1. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long-lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644-50.
2. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693-701. (Pubitemid 350035641)
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
4. Ishihara S, Watanabe T, Akahane T, et al. Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer. Int J Colorectal Dis. 2011;26(7):911-7.
5. Gabelova A, Farkasova T, Gurska S, Machackova Z, Lukacko P, Witkovsky V. Radiosensitivity of peripheral blood lymphocytes from healthy donors and cervical cancer patients; the correspondence of in vitro data with the clinical outcome. Neoplasma. 2008;55(3):182-91.
6. Bordon E, Henriquez Hernandez LA, Lara PC, et al 2009 Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol. 4:58.
7. Borgmann K, Hoeller U, Nowack S, et al. Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71(1):256-64.
8. Schnarr K, Boreham D, Sathya J, Julian J, Dayes IS. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2009;74(5):1424-30.
9. Ishihara S, Watanabe T, Kiyomatsu T, Yasuda K, Nagawa H. Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer. Int J Colorectal Dis. 2010;25(12):1417-25.
10. Fu CG, Tominaga O, Nagawa H, et al. Role of p53 and p21/ WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum. 1998;41(1): 68-74. (Pubitemid 28044878)
11. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9): 1750-5. (Pubitemid 46668536)
12. Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2007;69(4):1167-72. (Pubitemid 47625840)
13. Chang HJ, Jung KH, Kim DY, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005;36(4):364-71. (Pubitemid 40591806)
14. Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, Mochizuki H. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy. Dis Colon Rectum. 2007;50(9):1354-62. (Pubitemid 47472379)
15. Kim NK, Park JK, Lee KY, et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol. 2001;8(5):418-24.
16. Terzi C, Canda AE, Sagol O, et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis. 2008;23(1):37-45. (Pubitemid 350142358)
17. Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006;66(7):3370-4.
18. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23(9):1826-38. (Pubitemid 46217459)
19. Liersch T, Grade M, Gaedcke J, et al. Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenet. 2009;190(2):57-65.
20. Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol. 2010;5:47.
21. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008;248(2):243-51.
22. Dolinsky CM, Mahmoud NN, Mick R, et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol. 2007;96(3):207-12. (Pubitemid 350194618)
23. Suarez J, Vera R, Balen E, et al. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis. 2008;10(6):563-8. (Pubitemid 351803062)
24. Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2008 15(12):3471.
25. Topova L, Hellmich G, Puffer E, et al. Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum. 2011;54(4):401-11.
26. Tsujinaka S, Kawamura YJ, Konishi F, Aihara H, Maeda T, Mizokami K. Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer. Int J Colorectal Dis. 2008;23(1):67-76. (Pubitemid 350142362)
27. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47(11):1798-807. (Pubitemid 40064422)
28. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16(12):3488-98.